“…However, it should be noted that the inhibitory effects of the combined doxorubicin-barakol on MMP-3 activity and cell migration were not investigated in this work and should be further studied. The previous study reported that doxorubicin inhibited hepatic cancer cell (HepG2) migration by suppressing MMP-3 expression, and the inhibition was synergized by co-treatment with a natural-derived compound, trans -ferulic acid [ 66 ]. From this evidence, it is hypothesized that barakol, as an MMP-3 inhibitor, may potentiate the anti-metastatic effect of doxorubicin similarly.…”